Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Infectious Diseases

Nursing Home Acquired Pneumonia

Last Updated: May 12, 2006
Email to a Colleague
Synonyms and related keywords: nursing home–acquired pneumonia; NHAP, pneumonia in chronic care facilities, Streptococcus pneumoniae, S pneumoniae, Haemophilus influenzae, H influenzae, Moraxella catarrhalis, M catarrhalis, Legionella, Chlamydia pneumoniae, C pneumoniae, aspiration pneumonia, chronic bronchitis, CNS disease, esophageal disease, decreased gag reflex

  AUTHOR INFORMATION Section 1 of 10    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Author: Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York at Stony Brook School of Medicine; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD, MACP, is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Editor(s): Wesley W Emmons, MD, FACP, Assistant Professor, Department of Medicine, Thomas Jefferson University; Consulting Staff, Infectious Diseases Section, Department of Internal Medicine, Christiana Care, Newark, DE; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Ronald A Greenfield, MD, Chief, Professor, Department of Internal Medicine, Section of Infectious Disease, University of Oklahoma College of Medicine; Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Clinical Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital; and Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice

Disclosure


  INTRODUCTION Section 2 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Background: Nursing home–acquired pneumonia (NHAP) is defined as pneumonia occurring in a resident of a chronic care facility or nursing home. NHAP is one of the most common infectious disease problems in chronic care facilities. NHAP also is a significant cause of mortality and morbidity among residents of nursing homes or chronic care facilities. NHAP more closely resembles community-acquired pneumonia (CAP) than nosocomial pneumonia (NP).

NP occurs when the pathogen is distributed in a hospital setting, resulting in a subsequent infection. Aerobic gram-negative bacilli, including Pseudomonas aeruginosa, cause NPs. Staphylococcus aureus (eg, methicillin-susceptible S aureus [MSSA] and methicillin-resistant S aureus [MRSA]) infection is not a significant cause of CAP, NP, or NHAP. The presence of P aeruginosa and other aerobic gram-negative bacilli defines the NP group. Because NHAP is caused by CAP-associated pathogens and not NP-associated pathogens, NHAP is considered diagnostically and therapeutically synonymous to CAP. Patients with NHAP have the same length of hospital stay as patients with CAP. Physicians, therefore, approach the treatment strategy for NHAP and CAP in a similar way and with similar empiric antibiotic coverage.

Table 1. Comparison of Characteristics of Nursing Home–Acquired Pneumonia, Community-Acquired Pneumonia, and Nosocomial Pneumonia

Type of Pneumonia

Most Common Pathogens

Uncommon Pathogens

Appearance on Chest Radiograph

Length of Stay

NHAP

Streptococcus pneumoniae

Haemophilus influenzae

Moraxella catarrhalis

Legionella

Chlamydia pneumoniae

Focal sequential/lobar ± consolidation ± pleural effusion

No cavitation

7-10 days

CAP

S pneumoniae

H influenzae

M catarrhalis

Legionella

Mycoplasma

Focal sequential/lobar ± consolidation ± pleural effusion

No cavitation

7-10 days

NP

P aeruginosa

Klebsiella

Escherichia coli

Serratia

Necrotizing pneumonia and cavitation withP aeruginosa and Klebsiella

Bilateral infiltrates without cavitation or pleural effusion

10-21 days

Pathophysiology: The pathophysiology of NHAP is the same as the pathophysiology of CAP. NHAP may result when a patient aspirates oropharyngeal contents into one or more lung segments or lobes. NHAP also may occur if a distant focus of infection hematogenously disseminates to the lungs.

Aspiration pneumonia, whether community-acquired or acquired in a nursing home, results microbiologically from aspirated anaerobic oropharyngeal flora. Hundreds of species of oropharyngeal anaerobes may be cultured from patients with aspiration pneumonia. However, oropharyngeal anaerobes are not like Bacteroides fragilis, which is the primary anaerobe below the diaphragm and is sensitive to nearly all antibiotics. Patients with CAP or NHAP do not require specific anti–B fragilis coverage. In aspiration pneumonia, the location of the lung lesion is related to the position of the patient at the time of aspiration. Because most patients are supine when they aspirate, most lung infiltrates observed on chest radiographs and most aspiration pneumonia occur in segments of the right lung.

If aspiration occurs when patients are lying on their right side, the pulmonary infiltrates most likely involve the right upper lobe. If patients are lying on their left side, the most likely location of the infiltrates is the left upper lobe. If patients are supine and the aspiration is massive, bilateral infiltrates involving multiple lung segments or lobes are possible and may produce a radiologic appearance indistinguishable from left ventricular failure or acute respiratory distress syndrome.

Table 2. Radiographic Patterns in Aspiration Pneumonia

Patient Position at Aspiration

Chest Radiograph Lobar Involvement

Supine

Right lower lobe (ie, superior or posterior segment) or bilateral infiltrates (ie, all lobes)

Right side down

Right upper lobe (ie, axillary segment)

Left side down

Left upper lobe (ie, axillary segment)

Prone

Right middle lobe (ie, lingula)

Sitting upright

Right lower lobe (ie, basilar segments)

Hematogenously acquired pneumonia is not common among patients with CAP or NHAP. Hematogenously acquired pneumonia presents with bilateral symmetrical perihilar infiltrates, as opposed to the localized segmental or lobar distribution characteristic of pneumonia acquired via primary inhalation.

The degree of impaired lung function resulting from NHAP depends on the extent of aspiration and the patient's preexisting physiologic and anatomic lung function. The histologic changes in lung parenchyma resulting from NHAP are the same as those observed resulting from CAP (ie, no cavitation, necrosis, or blood vessel invasion). As with CAP, resolving NHAP restores the lung function that existed prior to acquiring pneumonia.

Frequency:

  • In the US: NHAP is one of the most common causes of infection in chronic care facilities and is one the most significant infection-related causes of mortality and morbidity in chronic care facilities.
  • Internationally: NHAP is a common cause of infection in chronic care facilities.

Mortality/Morbidity:

  • NHAP is one of the most important infection-related causes of mortality and morbidity in chronic care facilities.

Race:

  • No race predilection exists.

Sex:

  • No sex predilection exists.

Age:

  • By definition, most patients in chronic care facilities and nursing homes are elderly; therefore, NHAP is a disease that primarily afflicts elderly individuals.
  • NHAP is less common in chronic care or rehabilitation facilities that have smaller populations of elderly individuals.


  CLINICAL Section 3 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

History:

  • Patients may complain of fever, cough, chest pain, or rapid respiration.
  • Patients with chronic bronchitis are particularly prone to developing pneumonias.
  • Patients with aspiration NHAP often have a history of CNS or esophageal disease, or they have a decreased gag reflex that predisposes them to recurrent aspiration.

Physical:

  • Most, but not all, patients are febrile. Fever, when present, may be high-grade or low-grade.
  • Physical findings in the chest include rales over the involved lung segments with or without signs of consolidation or pleural effusion.

Causes:

  • The most common pathogens that cause NHAP and CAP are S pneumoniae, H influenzae, and M catarrhalis.
  • Atypical organisms that cause NHAP are Mycoplasma pneumoniae, Legionella (primarily in chronic care facilities), and C pneumoniae (primarily in elderly residents of nursing homes).
  • Overview of NHAP
    • NHAP is a common diagnosis applied upon admission but is the definitive diagnosis in only 33% of patients.
    • Many physicians perform a suboptimal workup for NHAP, omitting sputum Gram stains and culture studies. Blood cultures usually are negative.
    • The distribution of pathogens observed in NHAP more closely resembles CAP than NP.
    • Clinically, NHAP differs from NP in that NHAP is not associated with P aeruginosa, it does not produce cavitation on chest radiographs, and patients generally have a shorter hospital stay. The duration of the hospital stay for a patient with NHAP is the same as for a patient with CAP.
    • The medical conditions most frequently misdiagnosed as NHAP are congestive heart failure (CHF) and chronic obstructive pulmonary disease.
    • Chest radiograph findings in NHAP are useful to rule out CHF. Unilateral segmental or lobar infiltrates are the most common roentgenographic findings in NHAP, as they are in CAP.
    • Fever and leukocytosis are more common in patients with NHAP than in patients with noninfectious mimics of NHAP, but these findings are nonspecific.
    • Noninfectious infiltrates observed on chest radiographs frequently are misdiagnosed as NHAP.
    • Treat NHAP empirically, using the same antibiotics as with CAP, but not as with NP.
  DIFFERENTIALS Section 4 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Pleural Effusion
Pulmonary Embolism


Other Problems to be Considered:

Most patients from chronic care facilities who are transferred to acute care hospitals do not have NHAP. The most common causes of diagnostic confusion in patients with NHAP are noninfectious cardiac and pulmonary disorders.

CHF is the most common disorder that resembles NHAP in the chronic care facility setting. CHF may represent an exacerbation of preexisting CHF, resulting in increasing shortness of breath for the patient, which mimics the presentation of NHAP.

The clinical presentation of patients in nursing homes who develop asymptomatic acute myocardial infarctions also may mimic the clinical presentation of patients with NHAP. Myocardial infarction may be associated with fever, shortness of breath, and chest pain; all are signs that mimic NHAP.

Many elderly patients are unable to raise sputum, making the absence of a productive cough an inadequate determination to differentiate NHAP and CHF.

Preexisting lung disease, pulmonary emboli, and bronchogenic malignancies mimic NHAP. Collagen vascular diseases affecting the lungs, pulmonary drug reactions, and pulmonary hemorrhage also may mimic NHAP.

Chest radiographs are the best way to make the diagnosis of NHAP. Patients with NHAP have a segmental or lobar distribution of infiltrates, as seen on chest radiographs. Patients with CHF have a redistribution of vasculature to the upper lobes, usually accompanied by cardiomegaly. Verify cardiomegaly by physical examination. If CHF is present, it usually is accompanied by an S3 gallop rhythm.

Preexisting chest radiographs may reveal previous interstitial lung disease that may mimic the appearance of NHAP. Chest radiography is the primary tool for ruling out the mimics of pneumonia and any new or preexisting lung disorders.

Fever that is equal to or greater than 102°F and accompanied by pulmonary symptoms suggests NHAP, especially when accompanied by a productive cough. However, in elderly patients who are the usual residents of chronic care facilities, the febrile response may be blunted. Therefore, the absence of fever or the presence of a low-grade fever is unhelpful in differentiating NHAP and its mimics.

Pleural effusions occasionally cause diagnostic confusion in the diagnosis of pneumonia. Bacterial pneumonias, particularly infections with S pneumoniae and H influenzae, may be accompanied by pleural effusion. However, pleural effusions without associated infiltrates are not pneumonia. Bilateral pleural effusion rarely, if ever, results from an infectious etiology. The presence of bilateral pleural effusions with unilateral or bilateral pulmonary infiltrates suggests a noninfectious etiology, and the physician should work up the patient accordingly.

Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Bibliography

Click for related images.

Related Articles
Pleural Effusion

Pulmonary Embolism


Patient Education
Click here for patient education.



  WORKUP Section 5 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Lab Studies:

  • Blood cultures
    • Obtain blood cultures from all patients with CAP and NHAP.
    • Blood cultures usually are positive if infection with S pneumoniae or H influenzae is causing the patient's pneumonia.
    • The yield of positive blood cultures in NHAP is lower than in CAP, which may represent a difference in the time each culture was taken. Patients with CAP who are admitted to an acute care facility usually have blood cultures drawn in the emergency room or soon after admission. Patients who are transferred to an acute care hospital from a chronic care facility may not have blood cultures drawn for many hours or days after the onset of pneumonia. These factors may account for the difference in culture yields.
  • CBC test
    • Physicians usually obtain blood counts, but these tests are not helpful, because the results are nonspecific.
    • Leukocytosis with a left shift occurs as the result of stress to the individual, which may occur with NHAP, an acute myocardial infarction, pulmonary emboli, dehydration, or any cause of stress. Therefore, the clinician should not assume that just because leukocytosis with a left shift is present the patient has NHAP.
    • The diagnosis of NHAP rests on excluding the mimics of pneumonia and on the presence of characteristic findings on chest radiographs.
  • Sputum staining and culture
    • Stain sputum using a Gram stain and perform culture studies from patients with a productive cough who do not have chronic bronchitis.
    • Physicians cannot interpret sputum culture results from patients with chronic bronchitis because the results usually show normal flora or mixed flora, which is unhelpful to the clinician.
    • For sputum specimens to be useful in determining the etiology of the pneumonia, they must be of good quality and must reflect the lower respiratory tract flora. A poor specimen collection, as evidenced by the presence of epithelial squamous cell contamination and a relative lack of polymorphonuclear neutrophils or multiple organisms, suggests that the specimen is invalid and unreliable.
  • Multiple pathogens are not a feature of NHAP. Dual infections are rare in both NHAP and CAP.
  • Aspiration pneumonia resulting from anaerobic pharyngeal flora is the only polymicrobial respiratory tract infection that is considered community- or nursing home–acquired. The presence of a single causative pathogen generally excludes anaerobic aspiration pneumonia in both CAP and NHAP patients.

Imaging Studies:

  • Chest radiography is the primary tool to differentiate the mimics of pneumonia and NHAP. If the resolution of the chest radiograph is insufficient to differentiate NHAP, consider obtaining a chest CT scan.

Other Tests:

  • Obtain an ECG and cardiac enzymes in patients who may have a cardiac explanation for their pulmonary symptoms, as evidenced by their history, physical, or chest radiograph findings. ECG and cardiac enzymes are helpful for ruling out silent myocardial infarctions, which are not uncommon in elderly patients.
  • Bacterial blood gases or lung scans may be useful in ruling out pulmonary emboli as a cause of the patient's pulmonary symptoms.
  • If considering Legionnaire disease, a rare cause of sporadic pneumonia in chronic care facilities, obtain liver function tests.
  • Patients presenting with extrapulmonary findings in a chronic care facility may have NHAP caused by C pneumoniae infection. In such patients, C pneumoniae immunoglobulin (Ig) M and IgG titers may be diagnostic. IgA also may help to clarify if a patient is experiencing a relapse or a reinfection with Chlamydia. C pneumoniae infection usually occurs as part of an outbreak and should be readily recognizable in the nursing home setting because the infection occurs in clusters and is characterized by extrapulmonary features that set it apart from the usual bacterial causes of NHAP.

Procedures:

  • Patients with pleural effusions unrelated to a nephrotic syndrome, uremia, hypoalbuminemia, cirrhosis, or heart failure require diagnostic thoracentesis. Physicians should test the thoracentesis fluid using Gram stain and culture studies as well as pH, glucose, protein, cell count, and differential. This procedure may reveal the causal pathogen if blood cultures are negative and if sputum is not available.
Histologic Findings: Findings include local polymorphonuclear neutrophil infiltration of infected lung areas without cavitation, necrosis, or blood vessel invasion.

  TREATMENT Section 6 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical Care: If the physician suspects NHAP and the mimics of pneumonia can be ruled out, early appropriate empiric therapy is the critical component of medical management. Promptly instituting empiric antimicrobial therapy has significant impact on the mortality and morbidity of NHAP and CAP. Direct antimicrobial coverage against the most likely pathogens (ie, S pneumoniae, H influenzae, M catarrhalis, C pneumoniae).

Consultations:

Diet:

Activity:


  MEDICATION Section 7 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

The goals of pharmacotherapy are to reduce morbidity, eradicate the infection, and prevent complications.

Drug Category: Antibiotics -- Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the clinical setting.
Drug Name
Levofloxacin (Levaquin) -- Second-generation quinolone. Acts by interfering with DNA gyrase in bacterial cells. For pseudomonal infections and infections resulting from multi-drug–resistant gram-negative organisms. Highly active against gram-negative and gram-positive organisms, including highly penicillin-resistant S pneumoniae.
Adult Dose500 mg PO/IV qd for 7-14 d
Pediatric Dose<18 years: Not recommended
>18 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsAdminister antacids 1-2 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; levofloxacin reduces therapeutic effects of phenytoin; probenecid may increase levofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy
Drug Name
Ceftriaxone (Rocephin) -- Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to 1 or more penicillin-binding proteins.
Adult Dose1 g IV q24h
Pediatric DoseNeonates >7 days: 25-50 mg/kg/d IV/IM; not to exceed 125 mg/d
Infants and children: 100 mg/kg/d IV/IM divided q12h; not to exceed 2 g/d
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsGallbladder sludge (eg, pseudobiliary lithiasis) may require cholecystectomy; associated with non-C difficile diarrhea; adjust dose in renal impairment; caution in breastfeeding women and allergy to penicillin
Drug Name
Doxycycline (Vibramycin) -- Second-generation long-acting tetracycline. More active than tetracycline against many pathogens, especially S pneumoniae and Legionella. Different adverse effect profile and pharmacokinetics compared to tetracycline. Inhibits protein synthesis, thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.
Adult Dose100-200 mg PO/IV q12h
Pediatric Dose<8 years: Not recommended
>8 years: 2-5 mg/kg/d PO/IV in 1-2 divided doses; not to exceed 200 mg/d
ContraindicationsDocumented hypersensitivity; severe hepatic dysfunction
InteractionsBioavailability decreases minimally with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy
Pregnancy D - Unsafe in pregnancy
PrecautionsRarely, if ever, causes photosensitivity, but may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines
Drug Name
Cefepime (Maxipime) -- Fourth-generation cephalosporin with good gram-negative coverage. Similar to third-generation cephalosporins but has better gram-positive coverage.
Adult Dose2 g IV q12h
Pediatric Dose50 mg/kg IV q8h; not to exceed 2 g
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid at high dose decreases cefepime clearance; aminoglycosides increase nephrotoxic potential of cefepime
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsAdjust dose in severe renal insufficiency; prolonged use of cefepime may predispose patients to superinfection
  FOLLOW-UP Section 8 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Further Inpatient Care:

In/Out Patient Meds:

Transfer:

Deterrence/Prevention:

Complications:

Prognosis:

  MISCELLANEOUS Section 9 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical/Legal Pitfalls:

  • Do not assume that all patients with respiratory symptoms and infiltrates on their chest radiographs have pneumonia. Consider that patients may have one of the many mimics of pneumonia before embarking on a course of empiric antimicrobial therapy. If a physician treats a patient with empiric antimicrobial therapy when the patient has a treatable noninfectious cause for his or her pulmonary infiltrates, the patient may suffer because cardiac or noninfectious pulmonary conditions require other, non–anti-microbial, measures.

Special Concerns:

  • Remember that renal function decreases with age, and most patients in chronic care facilities are elderly; therefore, consider their creatinine clearance rate when calculating antimicrobial dosing.
  • The initial dose of renally cleared antibiotics in patients with renal insufficiency is the same as in individuals without renal insufficiency; however, physicians should decrease the maintenance dose in proportion to the degree of renal dysfunction. If using hepatically cleared antibiotics (eg, doxycycline) that primarily have a nonrenal mode of elimination, no dosing adjustment is necessary in elderly patients with impaired renal function.
  BIBLIOGRAPHY Section 10 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

  • Beck-Sague C, Villarino E, Giuliano D, et al: Infectious diseases and death among nursing home residents: results of surveillance in 13 nursing homes. Infect Control Hosp Epidemiol 1994 Jul; 15(7): 494-6[Medline].
  • Bonoan JT, Cunha BA: S. aureus as a cause of community-acquired pneumonia in patients with diabetes mellitus. Infectious Disease Practice 1999; 8: 319-321.
  • Buehrens PE: Effectiveness of oral antibiotic treatment in nursing-home acquired pneumonia. J Am Geriatr Soc 1995 Dec; 43(12): 1443; author reply 1443-4[Medline].
  • Crossley KB, Thurn JR: Nursing home-acquired pneumonia. Semin Respir Infect 1989 Mar; 4(1): 64-72[Medline].
  • Cunha BA: Pneumonia in the elderly. Drugs Today (Barc) 2000 Nov; 36(11): 785-91[Medline].
  • Cunha BA: Antibiotic Essentials. 5th ed. Royal Oak, Mich: Physicians Press; 2006.
  • Cunha BA: Penicillin resistant streptococcal pneumoniae nursing home acquired pneumonia. Emerg Med 2001; 33: 25-7.
  • Degelau J, Guay D, Straub K, Luxenberg MG: Effectiveness of oral antibiotic treatment in nursing home-acquired pneumonia. J Am Geriatr Soc 1995 Mar; 43(3): 245-51[Medline].
  • El Solh AA, Pietrantoni C, Bhat A, et al: Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 2004 Aug 15; 39(4): 474-80[Medline].
  • Fried TR, Gillick MR, Lipsitz LA: Whether to transfer? Factors associated with hospitalization and outcome of elderly long-term care patients with pneumonia. J Gen Intern Med 1995 May; 10(5): 246-50[Medline].
  • Garb JL, Brown RB, Garb JR, Tuthill RW: Differences in etiology of pneumonias in nursing home and community patients. JAMA 1978 Nov 10; 240(20): 2169-72[Medline].
  • Levinson ME: Pneumonias. In: Isselbacher KJ, Braunwald E, Wilson JD, eds. Harrison's Principles of Internal Medicine. 3rd ed. 1998; 1437-39.
  • Loeb M: Epidemiology of community- and nursing home-acquired pneumonia in older adults. Expert Rev Anti Infect Ther 2005 Apr; 3(2): 263-70[Medline].
  • Marrie TJ: Pneumonia in the elderly. Curr Opin Pulm Med 1996 May; 2(3): 192-7[Medline].
  • Marrie TJ, Slayter KL: Nursing home-acquired pneumonia. Treatment options. Drugs Aging 1996 May; 8(5): 338-48[Medline].
  • Marrie TJ, Blanchard W: A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc 1997 Jan; 45(1): 50-5[Medline].
  • McCue JD: Pneumonia in the elderly. Special considerations in a special population. Postgrad Med 1993 Oct; 94(5): 39-40, 43-6, 51[Medline].
  • Medina-Walpole AM, Katz PR: Nursing home-acquired pneumonia. J Am Geriatr Soc 1999 Aug; 47(8): 1005-15[Medline].
  • Meehan TP, Chua-Reyes JM, Tate J, et al: Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home- acquired pneumonia. Chest 2000 May; 117(5): 1378-85[Medline].
  • Mehr DR, Zweig SC, Kruse RL, et al: Mortality from lower respiratory infection in nursing home residents. A pilot prospective community-based study. J Fam Pract 1998 Oct; 47(4): 298-304[Medline].
  • Minnaganti VR, Patel PJ, Cunha BA: Nursing home-acquired pneumonia: Community-acquired or nosocomial? Infectious Disease Practice 2000; 24: 20-23.
  • Muder RR: Management of nursing home-acquired pneumonia: unresolved issues and priorities for future investigation [editorial; comment]. J Am Geriatr Soc 2000 Jan; 48(1): 95-6[Medline].
  • Muder RR: Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med 1998 Oct; 105(4): 319-30[Medline].
  • Mylotte JM, Naughton B, Saludades C, Maszarovics Z: Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia. J Am Geriatr Soc 1998 Dec; 46(12): 1538-44[Medline].
  • Mylotte JM, Goodnough S, Gould M: Pneumonia versus aspiration pneumonitis in nursing home residents: prospective application of a clinical algorithm. J Am Geriatr Soc 2005 May; 53(5): 755-61[Medline].
  • Phillips SL, Branaman-Phillips J: The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia. J Am Geriatr Soc 1993 Oct; 41(10): 1071-4[Medline].
  • Quagliarello V, Ginter S, Han L, et al: Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis 2005 Jan 1; 40(1): 1-6[Medline].
  • Ramirez JA: Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995 May-Jun; 22(1-2): 219-23[Medline].
  • Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M: Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999 Apr; 106(4): 385-90[Medline].
  • Thompson RS, Hall NK, Szpiech M: Hospitalization and mortality rates for nursing home-acquired pneumonia. J Fam Pract 1999 Apr; 48(4): 291-3[Medline].
  • Troy CJ, Peeling RW, Ellis AG, et al: Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997 Apr 16; 277(15): 1214-8[Medline].
  • Verghese A, Berk SL: Bacterial pneumonia in the elderly. Medicine (Baltimore) 1983 Sep; 62(5): 271-85[Medline].
  • Volicer L, Hurley AC: Risk factors for pneumonia in nursing home residents. J Am Geriatr Soc 1995 Dec; 43(12): 1443-4[Medline].
  • Zimmer JG, Hall WJ: Nursing home-acquired pneumonia: avoiding the hospital. J Am Geriatr Soc 1997 Mar; 45(3): 380-1[Medline].

Nursing Home Acquired Pneumonia excerpt